세계의 잠복성 결핵 진단 시장 : 분석별, 리스크 인자별, 실험실/장소별 - 시장 분석과 예측(2025-2029년), 주요 컨설턴트 가이드 포함

Latent TB Diagnostics Global Markets by Assay, by Risk Factor, and by Lab/Place. With Executive and Consultant Guides and Market Analysis and Forecasts 2025 - 2029

US $ 6,995 ￦ 9,961,000

PDF (Single User License)

PDF 보고서를 1명(One device)만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,495 ￦ 14,945,000

PDF (Five User License)

PDF 보고서를 동일 사업장의 5명(Five devices)까지 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 13,995 ￦ 19,930,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄는 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

잠복성 결핵 진단은 상용 제품을 생산하는 소수의 전통 기업이었습니다. 그러나 현재는 새로운 기술로서 새로운 틈새 시장이되었습니다.

이 보고서는 세계의 잠복성 결핵 진단 시장을 조사했으며, 시장 개요와 함께 분석별, 위험 인자별, 실험실/장소별 동향, 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 시장 가이드

제2장 소개와 시장 정의

• 결핵 진단의 개요
• 시장의 정의
• 조사 방법
• 헬스케어와 IVD 업계

제3장 결핵-현재 과학

• 결핵이란 무엇인가
• 진단
• 유병률

제4장 업계 개요

• 시장 진입기관
  • 학술연구기관
  • 진단 시험 개발자
  • 약품 및 시약 제조업체
  • 독립계 임상 실험실
  • 공공의 국립/지역 연구소
  • 병원 검사실
  • 임상 실험실
  • 감사기관
  • 인증기관

제5장 시장 동향

• 성장 촉진요인
• 성장 억제요인
• 진단 기술 개발

제6장 결핵 진단-최근 동향

제7장 주요 기업 프로파일

• AID GmbH
• Beijing Wantai
• bioMerieux Diagnostics
• Boditech Med, Inc
• Endo International
• Erythra
• Generium
• Glory Biotechnologies Corp.
• Lionex Diagnostics & Therapeutics GmbH
• Oxford Immunotec(Perkin Elmer)
• Perkin Elmer
• Qiagen
• R-Biopharm AG
• Sanofi
• SD Biosensor
• Serum Institute of India
• Statens Serum Institut
• Zhifei Longcom

제8장 세계의 잠복성 결핵 진단 시장 개요

• 세계의 잠복성 결핵 진단 시장 개요(국가별)
• 세계의 잠복성 결핵 진단 시장 개요(어세이별)
• 세계의 잠복성 결핵 진단 시장 개요(리스크 요인별)
• 세계의 잠복성 결핵 진단 시장 개요(랩별)

제9장 세계의 잠복성 결핵 진단 시장 - 분석별

• TST
• IGRA
• TBST
• 기타

제10장 세계의 잠복성 결핵 진단 시장-위험 요인별

• HIV
• 소아
• 당뇨병
• 이민
• 기타

제11장 세계의 잠복성 결핵 진단 시장- 실험실/장소별

• 병원 검사실
• 외래 검사실
• 포인트 오브 케어
• 기타 장소

제12장 부록

JHS

영문 목차

영문목차

Report Overview:

Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.

TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition?

The report forecasts the market size out five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. An Overview of TB Diagnostics
  • 2.1.1. The New Antigen Based TBST
• 2.2. Market Definition
  • 2.2.1. Market Size
  • 2.2.2. Currency
  • 2.2.3. Years
  • 2.2.4. Limitations
• 2.3. Methodology
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. Healthcare and the IVD Industry
  • 2.4.1. Global Healthcare Spending
  • 2.4.2. Spending on Diagnostics
  • 2.4.3. Important Role of Insurance for Diagnostics

3. Tuberculosis - Current Science

• 3.1. What is Tuberculosis?
  • 3.1.1. Causes
  • 3.1.2. Pathogenesis
  • 3.1.3. Prevention
  • 3.1.4. Treatment
• 3.2. Diagnosis
  • 3.2.1. Active TB
  • 3.2.2. Latent TB
• 3.3. Prevalence
  • 3.3.1. Impact of COVID on TB Prevalence

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Pharmaceutical/Reagent Supplier
  • 4.1.4. Independent Testing Lab
  • 4.1.5. Public National/regional lab
  • 4.1.6. Hospital lab
  • 4.1.7. Physician Lab
  • 4.1.8. Audit Body
  • 4.1.9. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Increasing Prevalence
  • 5.1.2. Increasing Diagnostic Options
  • 5.1.3. The Aging World
  • 5.1.4. Increased Health Care Spending
• 5.2. Factors Limiting Growth
  • 5.2.1. The Cost Curve Shrinks the Market
  • 5.2.2. The Diagnostics Dillemma
  • 5.2.3. Adoption Lag and Cost Control
• 5.3. Diagnostic Technology Development
  • 5.3.1. The Multiplex Opportunity
  • 5.3.2. Shifting Role of Physicians in Diagnosis
  • 5.3.3. Diagnostics Moves Out of the Lab
  • 5.3.4. Rapid Testing Changing Medical Practice
  • 5.3.5. The Next Five Years

6. TB Diagnostics - Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Danaher, Cepheid Urged to Further Reduce Price of TB Tests
• 6.3. Co-Diagnostics Submits At-Home PCR System
• 6.4. Iinnovation in TB research by Nanopore
• 6.5. New skin test for latent TB diagnostics
• 6.6. Latent TB Infection Screening Recommended
• 6.7. QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
• 6.8. PerkinElmer Hopes to Gain Market Share against Qiagen
• 6.9. PBD Biotech to Develop TB Blood Test
• 6.10. WHO Expands Assessment for TB MDx Developers
• 6.11. Cepheid Omni POC System Falls Off Radar
• 6.12. Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
• 6.13. NGeneBio Gets CE Mark for NGS-Based TB Assay
• 6.14. MDx TB Assay From PBD Biotech Shows Promise
• 6.15. Minute Molecular Dx to Launch Rapid PCR Test
• 6.16. Qiagen Next-Gen TB Test Gains Chinese Approval
• 6.17. FIND Invests $21M to Launch POC MDx Platforms
• 6.18. Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
• 6.19. Oxford Immunotec to Automate Latent TB Test
• 6.20. LumiraDx Eyes Test Menu Expansion
• 6.21. BioMerieux Targeting Hospitals With Desktop Latent TB Test

7. Profiles of Key Companies

• 7.1. AID GmbH
• 7.2. Beijing Wantai
• 7.3. bioMerieux Diagnostics
• 7.4. Boditech Med, Inc
• 7.5. Endo International
• 7.6. Erythra
• 7.7. Generium
• 7.8. Glory Biotechnologies Corp.
• 7.9. Lionex Diagnostics & Therapeutics GmbH
• 7.10. Oxford Immunotec (Perkin Elmer)
• 7.11. Perkin Elmer
• 7.12. Qiagen
• 7.13. R-Biopharm AG
• 7.14. Sanofi
• 7.15. SD Biosensor
• 7.16. Serum Institute of India
• 7.17. Statens Serum Institut
• 7.18. Zhifei Longcom

8. Latent TB Global Diagnostic Markets Overview

• 8.1. Latent TB Diagnostics - Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Latent TB Diagnostics Markets Overview by Assay
  • 8.2.1. Table - Global Market by Assay
  • 8.2.2. Chart - Global Market by Assay - Segments Growth
  • 8.2.3. Chart - Global Market by Assay - Share by Year
  • 8.2.4. Chart - Global Market by Assay
  • 8.2.5. Chart - Global Market by Assay - Base Year
  • 8.2.6. Chart - Global Market by Assay - Final Year
• 8.3. Global Latent TB Diagnostics Markets Overview by Risk Factor
  • 8.3.1. Table - Global Market by Risk Factor
  • 8.3.2. Chart - Global Market by Risk Factor - Segments Growth
  • 8.3.3. Chart - Global Market by Risk Factor - Share by Year
  • 8.3.4. Chart - Global Market by Risk Factor
  • 8.3.5. Chart - Global Market by Risk Factor - Base Year
  • 8.3.6. Chart - Global Market by Risk Factor - Final Year
• 8.4. Global Latent TB Diagnostics Markets Overview by Lab
  • 8.4.1. Table - Global Market by Lab
  • 8.4.2. Chart - Global Market by Lab - Segments Growth
  • 8.4.3. Chart - Global Market by Lab - Share by Year
  • 8.4.4. Chart - Global Market by Lab
  • 8.4.5. Chart - Global Market by Lab - Base Year
  • 8.4.6. Chart - Global Market by Lab - Final Year

9. Latent TB Diagnostic Market - by Assay

• 9.1. Latent TB Diagnostic - TST
  • 9.1.1. Table Latent TB Diagnostic TST - by Country
  • 9.1.2. Chart - Latent TB Diagnostic TST Growth
• 9.2. Latent TB Diagnostic - IGRA
  • 9.2.1. Table Latent TB Diagnostic IGRA - by Country
  • 9.2.2. Chart - Latent TB Diagnostic IGRA Growth
• 9.3. Latent TB Diagnostic - TBST
  • 9.3.1. Table Latent TB Diagnostic TBST - by Country
  • 9.3.2. Chart - Latent TB Diagnostic - TBST Growth
• 9.4. Latent TB Diagnostic -Other
  • 9.4.1. Table Latent TB Diagnostic Other - by Country
  • 9.4.2. Chart - Latent TB Diagnostic - Other Growth

10. Global Latent TB Diagnostics Markets - By Risk Factor

• 10.1. Latent TB Diagnostic - HIV
  • 10.1.1. Table Latent TB Diagnostic HIV - by Country
  • 10.1.2. Chart - Latent TB Diagnostic HIV Growth
• 10.2. Latent TB Diagnostic - Pediatric
  • 10.2.1. Table Latent TB Diagnostic Pediatric- by Country
  • 10.2.2. Chart - Latent TB Diagnostic Pediatric
• 10.3. Latent TB Diagnostic - Diabetes
  • 10.3.1. Table Latent TB Diagnostic Diabetes - by Country
  • 10.3.2. Chart - Latent TB Diagnostic - Diabetes Growth
• 10.4. Latent TB Diagnostic - Immigration
  • 10.4.1. Table Latent TB Diagnostic Immigration - by Country
  • 10.4.2. Chart - Latent TB Diagnostic - Immigration Growth
• 10.5. Latent TB Diagnostic - Other Risk Factor
  • 10.5.1. Table Latent TB Diagnostic Other Risk Factor - by Country
  • 10.5.2. Chart - Latent TB Diagnostic - Other Risk Factor Growth

11. Global Latent TB Diagnostics Markets - By Lab/Place

• 11.1. Latent TB Diagnostic - Hospital Lab
  • 11.1.1. Table Latent TB Diagnostic Hospital Lab - by Country
  • 11.1.2. Chart - Latent TB Diagnostic Hospital Lab Growth
• 11.2. Latent TB Diagnostic - Outpatient Lab
  • 11.2.1. Table Latent TB Diagnostic Outpatient Lab - by Country
  • 11.2.2. Chart - Latent TB Diagnostic Outpatient Lab Growth
• 11.3. Latent TB Diagnostic - Point of Care
  • 11.3.1. Table Latent TB Diagnostic Point of Care - by Country
  • 11.3.2. Chart - Latent TB Diagnostic Point of Care
• 11.4. Latent TB Diagnostic - Other Place
  • 11.4.1. Table Latent TB Diagnostic Other Place - by Country
  • 11.4.2. Chart - Latent TB Diagnostic Other Place

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule

관련자료